arGEN-X NL0010832176

Zai Lab, partner van ArgenX

1. Lang 15 november 2024 18:09

   auteur info

   • Lang

     Lid sinds: 19 mei 2014

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 907

     Gegeven: 881

   •    Aantal posts: 2.112

   Speciaal voor BL007
2. BLOO7 15 november 2024 18:55

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   :-) :-):-) Bedankt Lang.
   
   Janus Henderson Group:
   www.gurufocus.com/news/2603628/janus-...
   
   The firm acquired an additional 85,058,173 shares at a price of $24.14 each
   
   Iets onder de 25.50 uitgifte:
   www.benzinga.com/pressreleases/24/11/...
   
   Mijn gissing, vooraf reeds laten zakken tot 20% onder de nieuwste top na hun nieuwe instap van 30 september.
   En nu na nieuwe instap van nieuwe grootaandeelhouders in de public offering volle gas vooruit, mee op de goede verkopen van Vyvgart. de volgende kwartalen.
   
   Mijn mening dus.
3. BLOO7 15 november 2024 19:30

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   www.zailaboratory.com/
   
   asia.tools.euroland.com/tools/Pressre...
   
   VYVGART was $27.3 million in the third quarter of 2024, compared to $4.9 million for the same period in 2023, driven by increased sales since its launch in September 2023 and listing on NRDL for the treatment of gMG effective January 1, 2024.
4. BLOO7 19 november 2024 16:15

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   ir.zailaboratory.com/news-releases/ne...
5. BLOO7 22 november 2024 19:21

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   www.nasdaq.com/articles/zai-lab-pfize...
6. BLOO7 3 december 2024 16:07

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   finance.yahoo.com/news/zai-lab-novocu...
   
   Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
7. BLOO7 7 januari 2025 10:33

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   Dec 12, 2024
   Zai Lab Announces Participation in Investor Conference in January 2025
   PDF Version
   SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2024-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2025:
   
   43rd Annual J.P. Morgan Healthcare Conference
   Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST
   Location: San Francisco
   
   A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replay will be available for up to 30 days following the completion of the event.
   
   About Zai Lab
   
   Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
   
   For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
   
   View source version on businesswire.com: www.businesswire.com/news/home/202412...
   
   Investor Relations:
   Christine Chiou / Lina Zhang
   +1 (917) 886-6929 / +86 136 8257 6943
   christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com
   
   Media:
   Shaun Maccoun / Xiaoyu Chen
   +1 (857) 270-8854 / +86 185 0015 5011
   shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
   
   Source: Zai Lab Limited
8. BLOO7 10 januari 2025 23:05

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   ir.zailaboratory.com/news-releases/ne...
   
   Jan 10, 2025
   Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
   PDF Version
   -- Exclusive collaboration and licensing agreement for povetacicept in the region
   
   -- Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved
   
   SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Jan. 10, 2025-- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) with best-in-class potential being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases.
   
   This press release features multimedia. View the full release here: www.businesswire.com/news/home/202501...
   
   Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will utilize its extensive research and development expertise to help advance clinical trials and make regulatory submissions in the licensed territory. Leveraging its large commercial footprint, Zai Lab will be responsible for all commercialization activities in the licensed territory once pove becomes an approved product.
   
   “Zai Lab’s deep R&D and commercialization expertise, as well as infrastructure in the region, make them the ideal partner for Vertex as we work to bring pove to patients in China and the broader area,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “We are excited about this collaboration with Zai Lab, which will accelerate our ability to bring this potential best-in-class therapy to patients who are waiting.”
   
   “Pove is an important expansion of our portfolio as we continue to solidify our leading position in immunology in China,” said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We are committed to bringing innovative therapies to patients in need, and we are excited about this collaboration with Vertex to make pove available for patients in China and beyond.”
   
   ...
9. BLOO7 17 januari 2025 10:07

   auteur info

   • BLOO7

     Lid sinds: 28 mrt 2017

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 1470

     Gegeven: 1280

   •    Aantal posts: 5.837

   ir.zailaboratory.com/news-media/press...
   Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
   
   Jan 15, 2025